为了使常规短半衰期放射性核素Ｉｎ－１１３Ｍ能够用于ＲＩＩ研究，作者对传统ＲＩＩ方法进行改进，建立了ＤＴＰＡ预定位技术，即首先将抗肿瘤抗体在体外偶联，注入体内，待３天后抗体与肿瘤结合，再注入游离Ｉｎ－１１３Ｍ。Ｉｎ－１１３Ｍ可与Ａｂ上的ＤＴＰＡ结合，从而可在注射Ｉｎ－１１３Ｍ后２小时达到肿瘤显像效果。ＤＴＰＡ预定位技术的建立，简化了ＲＩＩ的研究方法，有利于ＲＩＩ研究从科研阶段走向临床应用。 In order to make the routine short half-life radionuclide In-113M can be used for RII research, the author improved the traditional RII method and established the DTPA pretargeting technology, that is, the anti-tumor antibody was firstly coupled in vitro and injected into the body. After three days, the antibody Combined with the tumor, and then injected free In-113M. In-113M binds to DTPA on Ab to achieve tumor imaging 2 hours after injection of In-113M. The establishment of DTPA pretargeting technology has simplified the research methods of RII and facilitated the RII research from the research stage to the clinical application.